Literature DB >> 22563728

Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.

T W Mc Gowan1, G P Pinchbeck, C M Mc Gowan.   

Abstract

REASONS FOR PERFORMING STUDY: The sensitivity and specificity of basal plasma α-melanocyte-stimulating hormone (α-MSH) and adrenocorticotrophic hormone (ACTH) for the diagnosis of pituitary pars intermedia dysfunction (PPID) has not been evaluated in a population-based study.
OBJECTIVES: To evaluate basal plasma α-MSH and ACTH concentrations for the diagnosis of PPID in a population of horses aged ≥ 15 years.
METHODS: Owner-reported data were obtained using a postal questionnaire distributed to an equestrian group. A subgroup of surveyed owners was visited and veterinary examination performed on horses aged ≥ 15 years. Blood samples were analysed for plasma α-MSH and ACTH concentrations. Seasonally adjusted cut-off values for α-MSH and ACTH concentrations for the diagnosis of PPID were obtained using Youden index values against a clinical gold standard diagnosis (hirsutism plus 3 or more clinical signs of PPID).
RESULTS: α-melanocyte-stimulating hormone and ACTH were highly correlated with each other and with clinical and historical indicators of PPID. The increase in both α-MSH and ACTH with increasing numbers of clinical signs in affected horses supports a spectrum of disease. Both variables were affected by season, with derived cut-off values being higher in autumn compared with other seasons. Sensitivity and specificity were moderate and good in nonautumn seasons (59 and 93%, respectively) for α-MSH using a cut-off of 52.0 pmol/l. Sensitivity and specificity were good in nonautumn seasons (80 and 83%, respectively) for ACTH using a cut-off of 29.7 pg/ml. For both α-MSH and ACTH, sensitivity and specificity were close to 100% for samples obtained during the autumn period. CONCLUSIONS AND POTENTIAL RELEVANCE: Basal plasma α-MSH and ACTH had moderate-to-good sensitivity and specificity for the diagnosis of PPID, which improved substantially during the autumn period, suggesting this may be the ideal time to test. Further studies to develop seasonally adjusted reference intervals for different geographical locations are warranted.
© 2012 EVJ Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22563728     DOI: 10.1111/j.2042-3306.2012.00575.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  11 in total

1.  Equine pituitary pars intermedia dysfunction: An international survey of veterinarians' approach to diagnosis, management, and estimated prevalence.

Authors:  James L Carmalt; Cheryl L Waldner; Andrew L Allen
Journal:  Can J Vet Res       Date:  2017-10       Impact factor: 1.310

2.  Relationship of skeletal muscle inflammation with obesity and obesity-associated hyperinsulinemia in horses.

Authors:  Heidi E Banse; Todd C Holbrook; Nicholas Frank; Dianne McFarlane
Journal:  Can J Vet Res       Date:  2016-07       Impact factor: 1.310

3.  Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.

Authors:  D I Rendle; M Duz; J Beech; T Parkin; A E Durham
Journal:  J Vet Intern Med       Date:  2014-10-13       Impact factor: 3.333

4.  The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies.

Authors:  Alexandra Meier; Dania Reiche; Melody de Laat; Christopher Pollitt; Donald Walsh; Martin Sillence
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

5.  Incidence and risk factors for recurrence of endocrinopathic laminitis in horses.

Authors:  Melody A de Laat; Dania B Reiche; Martin N Sillence; James M McGree
Journal:  J Vet Intern Med       Date:  2019-04-10       Impact factor: 3.333

6.  Phenotypic, hormonal, and clinical characteristics of equine endocrinopathic laminitis.

Authors:  Melody A de Laat; Martin N Sillence; Dania B Reiche
Journal:  J Vet Intern Med       Date:  2019-01-29       Impact factor: 3.333

7.  Effect of thyrotropin-releasing hormone stimulation testing on the oral sugar test in horses when performed as a combined protocol.

Authors:  Elizabeth Hodge; Alycia Kowalski; Catherine Torcivia; Sue Lindborg; Darko Stefanovski; Kelsey Hart; Nicholas Frank; Andrew van Eps
Journal:  J Vet Intern Med       Date:  2019-08-20       Impact factor: 3.333

8.  Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership.

Authors:  Rebecca C Tatum; Cathy M McGowan; Rachel S Dean; Joanne L Ireland
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

9.  Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses.

Authors:  Remona Horn; Allison J Stewart; Karen V Jackson; Elizabeth L Dryburgh; Carlos E Medina-Torres; François-René Bertin
Journal:  J Vet Intern Med       Date:  2020-12-24       Impact factor: 3.175

Review 10.  Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management.

Authors:  Caroline W Spelta
Journal:  Vet Med (Auckl)       Date:  2015-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.